maybe no approvals but i wouldn't call first half uneventful. so much hinges on otat. could be a major turning point. with a new, more focussed covid trial runnning there is a greater chance of success and no obvious roadblocks for gvhd share price. i think share price will run again well before any potential aproval dates if otat is positive. the short trades might have to start closing some positions. there might also be a number of big fish waiting for a clear pathway before they buy back in.
plus the novatris partnerships seems to waiting on otat which could be another strong price driver.
i suspect fda meetings regarding back pain have been pushed back . maybe 6 months or more hence very little discussion around that.
MSB Price at posting:
$1.56 Sentiment: None Disclosure: Held
(20min delay)